Only a pawn in their game: Orphan drug tax credit on the chopping block again under Dem spending bill
Buried about 1,600 pages into the version of the Build Back Better Act released yesterday afternoon is a pronounced tweak to the orphan drug tax credit that would sharply curtail which clinical testing expenses qualify for the credit.
The change comes amid a growing furor over blockbuster drugs racking up orphan indication approvals, and reaping the benefits of the tax credit while also pulling in tens of billions per year from other indications, like with AbbVie’s mega-blockbuster Humira, which has won 7 orphan indications and still has no competition in the US, or Roche’s blockbuster cancer drug Avastin, which has 11 orphan indications.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.